Cargando…

Immune Resistance and EGFR Antagonists in Colorectal Cancer

Targeting the epidermal growth factor receptor (EGFR) either alone or in combination with chemotherapy in patients with RAS wild type metastatic colorectal cancer (mCRC) has revolutionized the treatment of CRC, but with less results than initially envisaged. In recent years, the discovery of multipl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giordano, Guido, Remo, Andrea, Porras, Almudena, Pancione, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721348/ https://www.ncbi.nlm.nih.gov/pubmed/31370270 http://dx.doi.org/10.3390/cancers11081089

Ejemplares similares

Cancer-Associated Immune Resistance and Evasion of Immune Surveillance in Colorectal Cancer
por: Parcesepe, Pietro, et al.
Publicado: (2016)

Centrosome Dynamics and Its Role in Inflammatory Response and Metastatic Process
por: Pancione, Massimo, et al.
Publicado: (2021)

Immune Escape Mechanisms in Colorectal Cancer Pathogenesis and Liver Metastasis
por: Pancione, Massimo, et al.
Publicado: (2014)

Genetic and Epigenetic Events Generate Multiple Pathways in Colorectal Cancer Progression
por: Pancione, Massimo, et al.
Publicado: (2012)

Lymphocyte antigen 6G6D-mediated modulation through p38α MAPK and DNA methylation in colorectal cancer
por: Caruso, Francesca Pia, et al.
Publicado: (2022)

Targeting Angiogenesis and Tumor Microenvironment in Metastatic Colorectal Cancer: Role of Aflibercept
por: Giordano, Guido, et al.
Publicado: (2014)

Morphology and Molecular Features of Rare Colorectal Carcinoma Histotypes
por: Remo, Andrea, et al.
Publicado: (2019)

Crosstalk between the Tumor Microenvironment and Immune System in Pancreatic Ductal Adenocarcinoma: Potential Targets for New Therapeutic Approaches
por: Parente, Paola, et al.
Publicado: (2018)

Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer
por: Giordano, Guido, et al.
Publicado: (2015)

JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer
por: Giordano, Guido, et al.
Publicado: (2019)

Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era
por: Giordano, Guido, et al.
Publicado: (2021)

PPARG Epigenetic Deregulation and Its Role in Colorectal Tumorigenesis
por: Sabatino, Lina, et al.
Publicado: (2012)

The Role of Peroxisome Proliferator-Activated Receptors in the Esophageal, Gastric, and Colorectal Cancer
por: Fucci, Alessandra, et al.
Publicado: (2012)

Ensemble of Gene Signatures Identifies Novel Biomarkers in Colorectal Cancer Activated through PPARγ and TNFα Signaling
por: Pagnotta, Stefano Maria, et al.
Publicado: (2013)

Propensity for Early Metastatic Spread in Breast Cancer: Role of Tumor Vascularization Features and Tumor Immune Infiltrate
por: D’Andrea, Mario Rosario, et al.
Publicado: (2021)

Liquid Biopsy as a Tool Exploring in Real-Time Both Genomic Perturbation and Resistance to EGFR Antagonists in Colorectal Cancer
por: Internò, Valeria, et al.
Publicado: (2020)

Single-cell proteo-genomic reveals a comprehensive map of centrosome-associated spliceosome components
por: Cerulo, Luigi, et al.
Publicado: (2023)

The Immune System's Contribution to the Clinical Efficacy of EGFR Antagonist Treatment
por: MacDonald, Felicity, et al.
Publicado: (2017)

Loss of Primary Cilia Potentiates BRAF/MAPK Pathway Activation in Rhabdoid Colorectal Carcinoma: A Series of 21 Cases Showing Ciliary Rootlet CoiledCoil (CROCC) Alterations
por: Remo, Andrea, et al.
Publicado: (2023)

New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?
por: Bronte, Giuseppe, et al.
Publicado: (2015)

Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies
por: Zhou, Jing, et al.
Publicado: (2021)

Overcoming EGFR Resistance in Metastatic Colorectal Cancer Using Vitamin C: A Review
por: Machmouchi, Ahmad, et al.
Publicado: (2023)

Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
por: Zhao, Ben, et al.
Publicado: (2016)

Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions
por: Giordano, Guido, et al.
Publicado: (2017)

Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies
por: Leto, Simonetta M., et al.
Publicado: (2014)

Promotion or remission: a role of noncoding RNAs in colorectal cancer resistance to anti-EGFR therapy
por: Wei, Shanshan, et al.
Publicado: (2022)

Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance
por: Li, Qing-Hai, et al.
Publicado: (2020)

Right-sided rhabdoid colorectal tumors might be related to the Serrated Pathway
por: Pancione, Massimo, et al.
Publicado: (2013)

Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers
por: Misale, Sandra, et al.
Publicado: (2015)

EGFR Signaling in Colorectal Carcinoma
por: Krasinskas, Alyssa M.
Publicado: (2011)

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
por: Yang, Lu, et al.
Publicado: (2022)

A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors
por: Gelfo, Valerio, et al.
Publicado: (2016)

EGFR-Based Targeted Therapy for Colorectal Cancer—Promises and Challenges
por: Janani, Balakarthikeyan, et al.
Publicado: (2022)

Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer
por: Woolston, Andrew, et al.
Publicado: (2019)

The Winding Roadmap of Biomarkers Toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer
por: Antoniotti, Carlotta, et al.
Publicado: (2018)

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
por: Diaz, Luis A., et al.
Publicado: (2012)

Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer
por: Di Fiore, F, et al.
Publicado: (2010)

Molecular Characterization of Acquired Resistance to KRAS(G12C)–EGFR Inhibition in Colorectal Cancer
por: Yaeger, Rona, et al.
Publicado: (2023)

Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer
por: Lorenzato, Annalisa, et al.
Publicado: (2020)

Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer
por: Ciardiello, Davide, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9spsrbpba6a8pjs0ri1mtfalvm